Aera - About the company
Aera is a series B company based in Boston (United States), founded in 2021 by Feng Zhang. It operates as a Developer of genetic medicines across a wide range of therapeutic areas. Aera has raised $193M in funding from investors like Google Ventures, Lux Capital and Arch Venture Partners. The company has 680 active competitors, including 212 funded and 142 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Developer of genetic medicines across a wide range of therapeutic areas. The company is leveraging its proprietary protein nanoparticle (PNP) delivery platform to unlock the full potential of genetic medicines across more disease areas.
- Website
- aeratx.com
- Social
- Email ID
- *****@aeratx.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2021
Location
Boston, United States
Stage
Series B
Total Funding
$193M in 2 rounds
Latest Funding Round
Investors
Ranked
28th among 680 active competitors
Employee Count
90 as on Jul 31, 2026
Sign up to download Aera's company profile
Aera's funding and investors
Aera has raised a total funding of $193M over 2 rounds. Its first funding round was on Feb 16, 2023. Its latest funding round was a Series A round on Feb 16, 2023 for $*****. 3 investors participated in its latest round. Aera has 5 institutional investors.
Here is the list of recent funding rounds of Aera:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 16, 2023 | 2302687 | Series A | 7484452 | 3095453 | 3754830 | 1537711 |
Feb 16, 2023 | 8367673 | Series B | 4495772 | 4563607 |
Access funding benchmarks and valuations. Sign up today!View details of Aera's funding rounds and investors
Aera's founders and board of directors
Founder? Claim ProfileThe founders of Aera is Feng Zhang.
Here are the details of Aera's key team members:
- Feng Zhang: Founder of Aera. Contact Info: 1 email address
View details of Aera's Founder profiles and Board Members
Aera's employee count trend
Aera has 90 employees as of Jul 26. Here is Aera's employee count trend over the years:
Uncover Aera's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aera's Competitors and alternates
Top competitors of Aera include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Aera, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
5th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
8th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
9th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
10th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
28th |  Aera 2021, Boston (United States), Series B | Developer of genetic medicines across a wide range of therapeutic areas | $193M | 62/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Aera's competitors? Click here to see the top ones
Aera's Investments and acquisitions
Aera has made no investments or acquisitions yet.
Reports related to Aera
Here is the latest report on Aera's sector:
News related to Aera
Media has covered Aera for a total of 4 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.
•
•
Aera Therapeutics Presents Preclinical Data & Nominates AERA-109 for Autoimmune DiseasesBusiness Wire•Sep 24, 2025•Aera
•
•
Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific OfficerBusiness Wire•Sep 02, 2025•Aera
•
Feng Zhang gene-editing spinout closes $74M fundingThe Business Journals•Mar 18, 2025•Arbor Biotechnologies, Arch Venture Partners, TCG, Aera
•
•
Alnylam Vets Raise $193M to Solve Gene Therapy's Biggest Hurdle - DeliveryBioSpace•Feb 16, 2023•Alnylam, Arch Linux, Google Ventures, LUX and 3 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Aera
Explore our recently published companies
- Hockenden Farm Animal Feed - Sevenoaks based, 2022 founded, Deadpooled company
- Coastal City Collective - Unfunded company
- Curated Place Creative - San Francisco based, Unfunded company
- HUCAI - Switzerland based, 2021 founded, Unfunded company
- KLE - India based, Unfunded company
- Bentham Strategy - Shenzhen based, Unfunded company
